Xiaobing Chen

机构：Zhengzhou University, Henan Cancer Hospital · ORCID：0000-0002-6831-1417

发表论文 135 篇 · 总被引 1876 次 · h-index 23

代表论文

• HER2 + advanced gastric cancer: Current state and opportunities (Review) (2024 · International Journal of Oncology · 被引 22)
• Safety and preliminary efficacy results of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: A phase 1 dose escalation and expansion study. (2024 · Journal of Clinical Oncology · 被引 21)
• Integrative single-cell and bulk transcriptomes analyses reveals heterogeneity of serine-glycine-one-carbon metabolism with distinct prognoses and therapeutic vulnerabilities in HNSCC (2024 · International Journal of Oral Science · 被引 12)
• Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial (2025 · European Journal of Cancer · 被引 11)
• A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy (2025 · Antibody Therapeutics · 被引 10)
• Inhibition of Glycolysis Alleviates Chronic Unpredictable Mild Stress Induced Neuroinflammation and Depression-like Behavior (2024 · Brain Sciences · 被引 9)